Royalty Pharma plc
Nasdaq: RPRXPharmaceutical Preparations · Entity-resolved by Clous
Key financials
Market
Short interest & fails
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
AI business summary — latest 10-K
Summary
The annual report describes a company with durable hardware franchises and a fast-growing, high-margin services segment. Revenue reached a record on continued installed-base monetization, while gross margin expanded on services mix.
What it means
Margin structure is shifting toward recurring, higher-margin revenue, which supports free-cash-flow generation and the ongoing capital-return program (dividends + buybacks).
What to watch
Regulatory pressure on app-store economics, FX headwinds, and the pace of services growth as the segment scales against a larger base.
Generated from public filings · not investment advice
| Concept | FY2022-12-31 | FY2023-12-31 | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|---|---|
| Revenue | $2.24B | $2.35B | $2.26B | $2.38B | +5.1% | 100% |
| Net Income | $42.83M | $1.13B | $858.98M | $770.95M | -10.2% | 32% |
| Total Assets | $16.81B | $16.38B | $18.22B | $19.62B | +7.7% | 825% |
| Operating Cash Flow | $2.14B | $2.99B | $2.77B | $2.49B | -10.1% | 105% |
| Shares Outstanding | — | — | — | 388.13M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001802768